KR102673154B1 - 말초 신경의 IgG 자극된 재수초화 - Google Patents

말초 신경의 IgG 자극된 재수초화 Download PDF

Info

Publication number
KR102673154B1
KR102673154B1 KR1020227011045A KR20227011045A KR102673154B1 KR 102673154 B1 KR102673154 B1 KR 102673154B1 KR 1020227011045 A KR1020227011045 A KR 1020227011045A KR 20227011045 A KR20227011045 A KR 20227011045A KR 102673154 B1 KR102673154 B1 KR 102673154B1
Authority
KR
South Korea
Prior art keywords
ivig
neuropathy
polyclonal igg
igg
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227011045A
Other languages
English (en)
Korean (ko)
Other versions
KR20220045087A (ko
Inventor
패트릭 쿠에리
네베나 체코바
한스-페터 아르퉁
코리나 헤르만
비르기트 마리아 라이페르트
한스-페터 슈바르츠
하르트무트 에를리히
세바스티안 벙크
Original Assignee
다케다 야쿠힌 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다케다 야쿠힌 고교 가부시키가이샤 filed Critical 다케다 야쿠힌 고교 가부시키가이샤
Publication of KR20220045087A publication Critical patent/KR20220045087A/ko
Application granted granted Critical
Publication of KR102673154B1 publication Critical patent/KR102673154B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
KR1020227011045A 2012-02-29 2013-02-28 말초 신경의 IgG 자극된 재수초화 Active KR102673154B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261605117P 2012-02-29 2012-02-29
US61/605,117 2012-02-29
PCT/US2013/028350 WO2013130826A2 (en) 2012-02-29 2013-02-28 Igg stimulated remyelination of peripheral nerves
KR1020207030277A KR20200126005A (ko) 2012-02-29 2013-02-28 말초 신경의 IgG 자극된 재수초화

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207030277A Division KR20200126005A (ko) 2012-02-29 2013-02-28 말초 신경의 IgG 자극된 재수초화

Publications (2)

Publication Number Publication Date
KR20220045087A KR20220045087A (ko) 2022-04-12
KR102673154B1 true KR102673154B1 (ko) 2024-06-05

Family

ID=47884569

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020227011045A Active KR102673154B1 (ko) 2012-02-29 2013-02-28 말초 신경의 IgG 자극된 재수초화
KR1020147027130A Active KR102170615B1 (ko) 2012-02-29 2013-02-28 말초 신경의 IgG 자극된 재수초화
KR1020207030277A Ceased KR20200126005A (ko) 2012-02-29 2013-02-28 말초 신경의 IgG 자극된 재수초화

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020147027130A Active KR102170615B1 (ko) 2012-02-29 2013-02-28 말초 신경의 IgG 자극된 재수초화
KR1020207030277A Ceased KR20200126005A (ko) 2012-02-29 2013-02-28 말초 신경의 IgG 자극된 재수초화

Country Status (21)

Country Link
US (5) US8986670B2 (cg-RX-API-DMAC7.html)
EP (2) EP3590960B1 (cg-RX-API-DMAC7.html)
JP (3) JP6335800B2 (cg-RX-API-DMAC7.html)
KR (3) KR102673154B1 (cg-RX-API-DMAC7.html)
CN (4) CN104302666A (cg-RX-API-DMAC7.html)
AR (2) AR090211A1 (cg-RX-API-DMAC7.html)
AU (3) AU2013203088B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014021240A2 (cg-RX-API-DMAC7.html)
DK (2) DK2820042T3 (cg-RX-API-DMAC7.html)
EA (2) EA032000B1 (cg-RX-API-DMAC7.html)
ES (2) ES2943585T3 (cg-RX-API-DMAC7.html)
FI (1) FI3590960T3 (cg-RX-API-DMAC7.html)
HK (1) HK1248534A1 (cg-RX-API-DMAC7.html)
IL (3) IL277103B2 (cg-RX-API-DMAC7.html)
MX (2) MX369444B (cg-RX-API-DMAC7.html)
NZ (1) NZ629867A (cg-RX-API-DMAC7.html)
PL (2) PL2820042T3 (cg-RX-API-DMAC7.html)
PT (2) PT2820042T (cg-RX-API-DMAC7.html)
SG (1) SG11201405302WA (cg-RX-API-DMAC7.html)
TW (3) TWI700297B (cg-RX-API-DMAC7.html)
WO (1) WO2013130826A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3590960T3 (fi) * 2012-02-29 2023-04-25 Takeda Pharmaceuticals Co Perifeeristen hermojen IgG-stimuloitu remyelinaatio
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11511136B2 (en) 2017-11-17 2022-11-29 The Research Foundation For The State University Of New York Method for treating damaged peripheral nerves using x-ray microbeam irradiation
EP3908256A4 (en) * 2019-01-07 2022-09-21 Mallinckrodt Ard IP Unlimited Company METHOD TO PROMOTE REMYELINATION
GB201907882D0 (en) 2019-06-03 2019-07-17 Cyprus Foundation For Muscular Dystrophy Res Methods
EP4737584A1 (en) * 2023-06-30 2026-05-06 FUJIFILM Corporation Method for evaluating intercellular interaction of neuroinflammation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003070465A (ja) 2001-08-31 2003-03-11 Keio Gijuku シュワン細胞の培養方法
WO2005073252A1 (en) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Process for the manufacture of virus safe immunoglobulin

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (cg-RX-API-DMAC7.html) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
AT376367B (de) 1983-03-16 1984-11-12 Immuno Ag Verfahren zur herstellung von therapeutisch verabreichbaren, in endbehaeltern abgefuellten plasmaderivaten
DK166763B1 (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
ATE36457T1 (de) 1983-05-02 1988-09-15 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen krankheitserregern.
AT389815B (de) 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
AT390560B (de) 1986-05-30 1990-05-25 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
JP2871709B2 (ja) 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンg結合活性を有する新規な蛋白質プロテインh、該蛋白質をコードする遺伝子及び該蛋白質の製造法
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
WO1992003536A1 (en) * 1990-08-15 1992-03-05 University Of Miami And Its School Of Medicine Autotransplantation of schwann cells to promote nervous system repair
AT402891B (de) 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
EP0674531A1 (de) 1992-12-16 1995-10-04 IMMUNO Aktiengesellschaft Verfahren zur herstellung eines virussicheren biologischen präparates
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
HRP940645A2 (en) 1993-10-06 1996-12-31 Immuno Ag Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
ID27417A (id) 1998-06-09 2001-04-05 Statens Seruminstitut Proses untuk memproduksi immunoglobulin untuk pemberian melalui intravena dan produk-produk immunoglobulin lainnya
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
EP2287190B1 (en) * 2000-05-10 2014-12-17 Mayo Foundation For Medical Education And Research Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
JP2007521249A (ja) 2003-01-24 2007-08-02 エラン ファーマシューティカルズ,インコーポレイテッド 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療
CA2557229C (en) 2004-02-27 2012-07-10 Octapharma Ag A method of providing a purified, virus safe antibody preparation
EA017403B1 (ru) * 2007-02-02 2012-12-28 Байоджен Айдек Эмэй Инк. Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов
US7854703B2 (en) 2007-09-25 2010-12-21 Intel Corporation Peripheral neuropathy detection
CA2643496C (en) 2008-11-06 2015-02-03 Michael Fehlings The therapeutic use of igg as a neuroprotective agent
CN102021140B (zh) * 2009-09-18 2013-04-24 上海市第一人民医院 一种分离、纯化许旺细胞的方法
FI3590960T3 (fi) * 2012-02-29 2023-04-25 Takeda Pharmaceuticals Co Perifeeristen hermojen IgG-stimuloitu remyelinaatio

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003070465A (ja) 2001-08-31 2003-03-11 Keio Gijuku シュワン細胞の培養方法
WO2005073252A1 (en) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Process for the manufacture of virus safe immunoglobulin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Abstracts of ICCN 2010: 29th International Congress of Clinical Neurophysiology, Vol. 121, Supplement 1, Pages i, S1-S346 (October 2010),P12-11.*

Also Published As

Publication number Publication date
TWI700297B (zh) 2020-08-01
JP6335800B2 (ja) 2018-05-30
KR20140134690A (ko) 2014-11-24
AU2016201137A1 (en) 2016-03-10
CN107551269A (zh) 2018-01-09
AU2013203088B2 (en) 2015-12-03
ES2755056T3 (es) 2020-04-21
SG11201405302WA (en) 2014-09-26
US20150232536A1 (en) 2015-08-20
MX369444B (es) 2019-11-08
DK3590960T3 (da) 2023-04-24
AR090211A1 (es) 2014-10-29
EA032000B1 (ru) 2019-03-29
US20180291087A1 (en) 2018-10-11
PT2820042T (pt) 2019-10-31
IL274512A (en) 2020-06-30
AU2018200026B2 (en) 2019-12-05
EP3590960B1 (en) 2023-03-29
JP6979990B2 (ja) 2021-12-15
AU2018200026A1 (en) 2018-01-25
IL277103B1 (en) 2025-03-01
JP2015508824A (ja) 2015-03-23
FI3590960T3 (fi) 2023-04-25
MX2019012496A (es) 2020-01-20
IL274512B2 (en) 2024-07-01
JP2020059705A (ja) 2020-04-16
WO2013130826A2 (en) 2013-09-06
CN110343171A (zh) 2019-10-18
IL234303B (en) 2020-09-30
PL2820042T3 (pl) 2020-03-31
US20200216518A1 (en) 2020-07-09
WO2013130826A3 (en) 2013-12-05
US20210300997A1 (en) 2021-09-30
PL3590960T3 (pl) 2023-07-17
AR117207A2 (es) 2021-07-21
EA201892521A1 (ru) 2019-07-31
EP2820042B1 (en) 2019-07-24
KR102170615B1 (ko) 2020-10-28
BR112014021240A2 (pt) 2018-09-18
AU2013203088A1 (en) 2013-09-19
KR20220045087A (ko) 2022-04-12
KR20200126005A (ko) 2020-11-05
JP6637934B2 (ja) 2020-01-29
DK2820042T3 (da) 2019-10-28
AU2016201137B2 (en) 2017-10-12
US9834593B2 (en) 2017-12-05
TW201400502A (zh) 2014-01-01
TW201838654A (zh) 2018-11-01
NZ629867A (en) 2016-09-30
MX2014010387A (es) 2015-09-25
EP2820042A2 (en) 2015-01-07
IL274512B1 (en) 2024-03-01
JP2018030856A (ja) 2018-03-01
TWI632158B (zh) 2018-08-11
US10494418B2 (en) 2019-12-03
IL277103B2 (en) 2025-07-01
EA201400966A1 (ru) 2014-12-30
US8986670B2 (en) 2015-03-24
IL277103A (en) 2020-10-29
HK1206035A1 (en) 2015-12-31
TW201736398A (zh) 2017-10-16
CN109966488A (zh) 2019-07-05
EP3590960A1 (en) 2020-01-08
US20130224150A1 (en) 2013-08-29
CN104302666A (zh) 2015-01-21
PT3590960T (pt) 2023-04-18
HK1248534A1 (zh) 2018-10-19
ES2943585T3 (es) 2023-06-14

Similar Documents

Publication Publication Date Title
US20210300997A1 (en) IgG STIMULATED REMYELINATION OF PERIPHERAL NERVES
US9775899B2 (en) Treating neurological disorders
JP5885923B2 (ja) 免疫応答を低減して免疫状態を治療する方法
HK40018190B (en) Igg stimulated remyelination of peripheral nerves
HK40018190A (en) Igg stimulated remyelination of peripheral nerves
HK1206035B (en) Igg stimulated remyelination of peripheral nerves
EA040995B1 (ru) Ремиелинизация периферических нервов, стимулированная igg

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000